Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2012
05/02/2012CN101721433B Double-mushroom polysaccharide preparation containing flammulina velutipes polysaccharide and lentinan polysaccharide and preparation method and application thereof
05/02/2012CN101574444B Rehabilitation medication combination for curing addiction to morphine drugs and preparation method thereof
05/02/2012CN101574443B Rehabilitation medication combination for curing addiction to morphine drugs and preparation method thereof
05/02/2012CN101530441B Chinese medicine composition capable of treating insomnia
05/02/2012CN101485695B Guiling dispersible tablets and preparation method thereof
05/02/2012CN101480415B Cordyceps sinensis sustained and controlled release capsule and preparation method thereof
05/02/2012CN101198331B Solubilization preparation
05/01/2012US8168827 Amide derivative
05/01/2012US8168820 Deuterated catecholamine derivatives and medicaments comprising said compounds
05/01/2012US8168803 Methods of using [3.2.0] heterocyclic compounds and analogs thereof
05/01/2012US8168786 Radiolabeled compounds and uses thereof
05/01/2012US8168776 Method for making a 21 nucleotide double stranded RNA chemically linked at one end
05/01/2012US8168641 Aspartyl protease inhibitors
05/01/2012US8168637 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes
05/01/2012US8168629 Analgesic combination of tramadol and meloxicam
05/01/2012US8168628 Conjugated psychotropic drugs and uses thereof
05/01/2012US8168610 Bispecific oligonucleotide for the treatment of CNS malignancies
05/01/2012US8168589 Use of erythropoietin and substances increasing and/or prolonging the activation and/or stimulation of erythropoietin receptors for treating and/or preventing schizophrenia and related psychoses
05/01/2012US8168189 Protein A compositions and methods of use
05/01/2012CA2698384C 3-pyridyl enantiomers and their use as analgesics
05/01/2012CA2660577C Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone
05/01/2012CA2652981C Robust sustained release formulations
05/01/2012CA2599156C Dosage form containing oxycodone and naloxone
05/01/2012CA2532648C A stable clozapine suspension formulation
05/01/2012CA2509413C Benzazepine derivatives for the treatment of neurological disorders
05/01/2012CA2493789C Anthranyl derivatives having an anti cholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof
05/01/2012CA2493402C Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same
05/01/2012CA2490722C Novel benzimidazole derivatives
05/01/2012CA2485217C Insulin-associated peptides with effects on cerebral health
05/01/2012CA2455633C Sustained-release therapeutic bioadhesive systems
05/01/2012CA2429625C Hematopoietic cell e-selectin/l-selectin ligand polypeptides and methods of use thereof
05/01/2012CA2404212C A process for the preparation of epothilone analogs and intermediates
05/01/2012CA2400559C Humanized antibodies that sequester .alpha..beta. peptide
05/01/2012CA2379858C Beta-amyloid peptide inhibitors
05/01/2012CA2333466C Gbs toxin receptor
05/01/2012CA2281620C Neurturin receptor
05/01/2012CA2279555C Amyloid beta protein (globular assembly and uses thereof)
04/2012
04/26/2012WO2012054739A2 Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
04/26/2012WO2012054724A1 Methods of treating seizure disorders
04/26/2012WO2012054721A1 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
04/26/2012WO2012054566A2 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
04/26/2012WO2012054535A2 Compounds, compositions and methods useful for cholesterol mobilisation
04/26/2012WO2012054530A2 Chemosensory receptor ligand-based therapies
04/26/2012WO2012054528A2 Chemosensory receptor ligand-based therapies
04/26/2012WO2012054527A2 Chemosensory receptor ligand-based therapies
04/26/2012WO2012054510A1 Oxadiazole compounds which inhibit beta-secretase activity and methods of use thereof
04/26/2012WO2012054446A2 Combination therapy
04/26/2012WO2012053727A1 Composition including nicotinamide as an active ingredient for preventing or treating alkylating agent-induced apoptotic neurodegeneration
04/26/2012WO2012053186A1 Arylamide derivatives as ttx-s blockers
04/26/2012WO2012052596A1 Ganglioside derivatives and use thereof as inhibitors of tumour cell division
04/26/2012WO2012052556A1 Novel haloalkoxyquinazolines, and preparation and use thereof
04/26/2012WO2012052540A1 Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
04/26/2012WO2012052169A2 Particulate pharmaceutical composition containing an opioid and an opioid antagonist
04/26/2012WO2012052167A1 Substituted 6-amino-nicotinamides as kcnq2/3 modulators
04/26/2012WO2012051745A1 A method of extracting bioactive substances by breaking wall of chlorella pyrenoidosa
04/26/2012WO2012030050A3 Pharmaceutical composition for the prevention or treatment of degenerative neurological brain disorders
04/26/2012WO2012027811A3 Anesthetic association, anesthetic composition, and anesthetic medicament for veterinary use
04/26/2012WO2012027794A3 Method of treatment and agents useful for same
04/26/2012WO2012014078A3 Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
04/26/2012WO2012010978A3 A method of treating alzheimer's disease
04/26/2012WO2012010970A3 A method of treating attention deficit hyperactivity disorder
04/26/2012WO2012006550A3 Methods and compositions for treatment of lipogenic virus related conditions
04/26/2012WO2012006117A3 Reduction of microglia-mediated neurotoxicity by kca3.1 inhibition
04/26/2012WO2012002688A3 Methods of treating restless legs syndrome
04/26/2012WO2012002687A3 Methods for treating bipolar disorder
04/26/2012WO2012002680A3 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors
04/26/2012WO2011156786A3 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
04/26/2012WO2011156640A3 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
04/26/2012WO2011152657A3 Acetyl-l-carnitine malate, process for preparing the same, and pharmaceutical composition comprising the same
04/26/2012WO2009156861A8 Substituted pyrimidone derivatives
04/26/2012WO2009118657A8 Polymorphic form of an aminoindan mesylate derivative
04/26/2012US20120101327 Apparatus and method for pulsed electrical field treatment
04/26/2012US20120101172 Liquid or pourable proteosome-forming bath and shower concentrates, galenic application products thereof, and their use
04/26/2012US20120101168 Deuterium enriched rasagiline
04/26/2012US20120101161 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
04/26/2012US20120101154 Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
04/26/2012US20120101152 Neurite elongation agent, memory-improving agent and anti-alzheimer agent comprising 4'-demethylnobiletin or 4'-demethyltangeretin as active ingredient, and process for production of the compound
04/26/2012US20120101149 Betulinic Acid Derivatives and Methods of Use Thereof
04/26/2012US20120101147 Inhibition of hdac2 to promote memory
04/26/2012US20120101146 Pharmaceutical composition comprising rotigotine salts (acid or na), especially for iontophoresis
04/26/2012US20120101138 Fluorinated aminotriazole derivatives
04/26/2012US20120101136 5-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
04/26/2012US20120101134 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
04/26/2012US20120101132 New Substituted Oxindole Derivative
04/26/2012US20120101125 Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
04/26/2012US20120101124 1,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
04/26/2012US20120101123 Compounds
04/26/2012US20120101121 drug demonstrating anxiolytic effect based on hydrogenated pyrido (4,3-b) indoles, its pharmacological compound and application method
04/26/2012US20120101118 Tamper resistant dosage forms
04/26/2012US20120101115 Compounds For Inducing Cellular Apoptosis
04/26/2012US20120101112 SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
04/26/2012US20120101111 Novel oxazolidinone deriviatives
04/26/2012US20120101110 Diaza-spiro[5.5]undecanes
04/26/2012US20120101107 Piperazine dithioctate and pharmaceutical composition comprising the same
04/26/2012US20120101106 Tetrahydronapthyridine Orexin Receptor Antagonists
04/26/2012US20120101105 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
04/26/2012US20120101101 Therapeutic agent for motor disorders
04/26/2012US20120101095 Alkoxy-thienopyrimidines as tgf-beta receptor kinase modulators
04/26/2012US20120101094 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
04/26/2012US20120101093 Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
1 ... 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 ... 1833